Autoimmune cholangitis and cholangiocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 12, 2012, Pages 1783-1789

  Li, Jun ^a   Zhao, Chaochen ^a   Shen, Yuechun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Cholangitis; Immunoglobulin G4

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN G4;

ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOIMMUNE CHOLANGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE PANCREATITIS; BILE DUCT CARCINOMA; CELL INFILTRATION; CHOLANGITIS; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RETROPERITONEUM; REVIEW; STEROID THERAPY; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLANGITIS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; HUMANS; IMMUNOGLOBULIN G;

EID: 84869839597     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07287.x     Document Type: Review

References (62)

1. Kamisawa T, Funata N, Hayashi Y etal. A new clinicopathological entity of IgG4-related autoimmune disease. J. Gastroenterol. 2003; 38: 982-984.
2. Ghazale A, Chari ST, Zhang L etal. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715.
3. Hamano H, Kawa S, Uehara T etal. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest. Endosc. 2005; 62: 152-157.
4. Miura H, Miyachi Y. IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis. A recurrent case after a 5-year history of spontaneous remission. JOP 2009; 10: 432-437.
5. Chung DT, Tang CN, Lai EC etal. Immunoglobulin G4-associated sclerosing cholangitis mimicking cholangiocarcinoma. Hong Kong Med. J. 2010; 16: 149-152.
6. Zen Y, Harada K, Sasaki M etal. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am. J. Surg. Pathol. 2004; 28: 1193-1203.
7. Fujita T, Kojima M, Gotohda N etal. Incidence, clinical presentation and pathological features of benign sclerosing cholangitis of unknown origin masquerading as biliary carcinoma. J. Hepatobiliary Pancreat. Sci. 2010; 17: 139-146.
8. Erdogan D, Kloek JJ, ten Kate FJ etal. Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. Br. J. Surg. 2008; 95: 727-734.
9. Stathopoulos G, Nourmand AD, Blackstone M etal. Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor. J. Clin. Gastroenterol. 1995; 21: 143-148.
10. Kawaguchi K, Koike M, Tsuruta K etal. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum. Pathol. 1991; 22: 387-395.
11. Nieminen U, Koivisto T, Kahri A etal. Sjogren's syndrome with chronic pancreatitis, sclerosing cholangitis, and pulmonary infiltrations. Am. J. Gastroenterol. 1997; 92: 139-142.
12. Nakazawa T, Ohara H, Sano H etal. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest. Endosc. 2004; 60: 937-944.
13. Sarles H, Sarles JC, Muratore R etal. Chronic inflammatory sclerosis of the pancreas-an autonomous pancreatic disease? Am. J. Dig. Dis. 1961; 6: 688-698.
14. Yoshida K, Toki F, Takeuchi T etal. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig. Dis. Sci. 1995; 40: 1561-1568.
15. Chari ST, Smyrk TC, Levy MJ etal. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin. Gastroenterol. Hepatol. 2006; 4: 1010-1016.
16. Ibrahim SH, Zhang L, Freese DK. A 3-year-old with immunoglobulin G4-associated cholangitis. J. Pediatr. Gastroenterol. Nutr. 2011; 53: 109-111.
17. Bjornsson E. Immunoglobulin G4-associated cholangitis. Curr. Opin. Gastroenterol. 2008; 24: 389-394.
18. Hufnagel M, Henneke P, Schmitt-Graeff A. IgG4-related disease. N. Engl. J. Med. 2012; 366: 1643-1644.
19. Niks EH, De Baets MH, Verschuuren JJ. IgG4-related disease. N. Engl. J. Med. 2012; 366: 1644-1645.
20. Vaglio A, Zwerina J. IgG4-related disease. N. Engl. J. Med. 2012; 366: 1646-1647.
21. Divatia M, Kim SA, Ro JY. IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease. Yonsei Med. J. 2012; 53: 15-34.
22. Vlachou PA, Khalili K, Jang HJ etal. IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics 2011; 31: 1379-1402.
23. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J. Gastroenterol. 2006; 41: 613-625.
24. Sah RP, Pannala R, Chari ST etal. Prevalence, diagnosis, and profile of autoimmune pancreatitis presenting with features of acute or chronic pancreatitis. Clin Gastroenterol Hepatol. 2010; 8: 91-96.
25. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J. Gastroenterol. 2007; 42 (Suppl. 18): 39-41.
26. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: diagnosis and management. Curr. Gastroenterol. Rep. 2006; 8: 75-82.
27. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 2006; 26: 31-41.
28. Bambha K, Kim WR, Talwalkar J etal. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369.
29. Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J. Gastroenterol. 2007; 13: 5421-5431.
30. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin. Immunopathol. 2009; 31: 383-397.
31. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667.
32. Li J, Zhao CC, Wang XM, Chen JH, Li XC, Shen YC. Hepatobiliary and pancreatic: autoimmune cholangitis, pancreatitis and sialadenitis. J. Gastroenterol. Hepatol. 2012; 27: 988.
33. Nishino T, Oyama H, Hashimoto E etal. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J. Gastroenterol. 2007; 42: 550-559.
34. Shin HR, Oh JK, Masuyer E etal. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010; 101: 579-585.
35. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
36. Lim JH, Park CK. Pathology of cholangiocarcinoma. Abdom. Imaging 2004; 29: 540-547.
37. Cox H, Ma M, Bridges R etal. Well differentiated intrahepatic cholangiocarcinoma in the setting of biliary papillomatosis: a case report and review of the literature. Can. J. Gastroenterol. 2005; 19: 731-733.
38. Bond GG, McLaren EA, Sabel FL etal. Liver and biliary tract cancer among chemical workers. Am. J. Ind. Med. 1990; 18: 19-24.
39. Burak K, Angulo P, Pasha TM etal. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 2004; 99: 523-526.
40. Shaib YH, El-Serag HB, Davila JA etal. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626.
41. Rubel LR, Ishak KG. Thorotrast-associated cholangiocarcinoma: an epidemiologic and clinicopathologic study. Cancer 1982; 50: 1408-1415.
42. Jaiswal M, LaRusso NF, Burgart LJ etal. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; 60: 184-190.
43. Prawan A, Kukongviriyapan V, Tassaneeyakul W etal. Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur. J. Cancer Prev. 2005; 14: 245-250.
44. Tocchi A, Mazzoni G, Liotta G etal. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1000 patients. Ann. Surg. 2001; 234: 210-214.
45. Bettschart V, Clayton RA, Parks RW etal. Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease. Gut 2002; 51: 128-129.
46. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J. Clin. Oncol. 2005; 23: 4742-4754.
47. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin. Liver Dis. 1991; 11: 26-30.
48. Boberg KM, Bergquist A, Mitchell S etal. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand. J. Gastroenterol. 2002; 37: 1205-1211.
49. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 2006; 56: 69-83.
50. Wise C, Pilanthananond M, Perry BF etal. Mechanisms of biliary carcinogenesis and growth. World J. Gastroenterol. 2008; 14: 2986-2989.
51. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin. Liver Dis. 1994; 14: 109-114.
52. Vosskuhl K, Negm AA, Framke T etal. Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy 2012; 44: 48-52.
53. Levy C, Lymp J, Angulo P etal. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 2005; 50: 1734-1740.
54. Locker GY, Hamilton S, Harris J etal. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006; 24: 5313-5327.
55. Tangkijvanich P, Thong-ngam D, Theamboonlers A etal. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 2004; 51: 15-19.
56. Chuang CK, Liao SK. Evaluation of CA19-9 as a tumor marker in urothelial malignancy. Scand. J. Urol. Nephrol. 2004; 38: 359-365.
57. Souchon R, Koppenhagen K, Souchon MF etal. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients. Cancer Detect. Prev. 1985; 8: 101-109.
58. Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim. Pol. 2002; 49: 303-311.
59. Perkins GL, Slater ED, Sanders GK etal. Serum tumor markers. Am. Fam. Physician 2003; 68: 1075-1082.
60. Howaizi M, Abboura M, Krespine C etal. A new cause for CA19.9 elevation: heavy tea consumption. Gut 2003; 52: 913-914.
61. Murohisa T, Sugaya H, Tetsuka I etal. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern. Med. 1992; 31: 516-520.
62. Sawai H, Matsubayashi H, Sasaki K etal. A case of sclerosing cholangitis without pancreatic involvement thought to be associated with autoimmunity. Intern. Med. 2011; 50: 433-438.